Oncology Institute (TOI) grants 29,116 RSUs to company director
Rhea-AI Filing Summary
TZOUMAKAS KIMBERLY JO reported acquisition or exercise transactions in this Form 4 filing.
Oncology Institute, Inc. director TZOUMAKAS KIMBERLY JO received a grant of 29,116 restricted stock units on July 27, 2026, each entitling her to one share of common stock upon settlement. These RSUs vest in full at the 2027 annual meeting of stockholders, bringing her direct holdings to 46,301 shares.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 29,116 shares
Net Buy
1 txn
Insider
TZOUMAKAS KIMBERLY JO
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock F1 | 29,116 | $0.00 | $0.00 |
Holdings After Transaction:
Common Stock — 46,301 shares (Direct)
Footnotes (1)
- F1. Represents grant of restricted stock units (RSUs), each of which entitle the Reporting Person to receive one share of the Issuer's common stock upon settlement. The RSUs vest in full on the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continued service with the Issuer on the vesting date.
Key Figures
RSUs granted: 29,116 shares
Grant price: $0.0000 per share
Direct holdings after grant: 46,301 shares
+1 more
4 metrics
RSUs granted
29,116 shares
Grant of restricted stock units on 2026-07-27
Grant price
$0.0000 per share
Reported transaction price for RSU award
Direct holdings after grant
46,301 shares
Common stock directly held following the RSU grant
Vesting year
2027
RSUs vest in full at the 2027 annual meeting of stockholders
Key Terms
restricted stock units (RSUs), vest in full, annual meeting of stockholders
3 terms
restricted stock units (RSUs) financial
"Represents grant of restricted stock units (RSUs), each of which entitle"
Restricted stock units (RSUs) are a type of company promise to give employees shares of stock in the future, usually after certain conditions like working for a set time. They are like a gift promised today that you receive later, which can become valuable if the company's stock price goes up. RSUs matter because they are a way companies reward employees and can be a significant part of compensation.
vest in full financial
"The RSUs vest in full on the date of the Issuer's 2027"
annual meeting of stockholders regulatory
"on the date of the Issuer's 2027 annual meeting of stockholders"
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider transaction did TOI report for director TZOUMAKAS KIMBERLY JO?
Director TZOUMAKAS KIMBERLY JO received 29,116 restricted stock units of Oncology Institute, Inc. (TOI) on July 27, 2026. These RSUs convert into common stock on settlement and vest fully at the company’s 2027 annual meeting of stockholders.
When do the 29,116 RSUs granted by TOI to its director vest?
The 29,116 restricted stock units granted to the director vest in full on the date of Oncology Institute’s 2027 annual meeting of stockholders, conditioned on the director’s continued service with the company through that vesting date.
What does each RSU granted by Oncology Institute (TOI) to the director represent?
Each of the 29,116 restricted stock units entitles the reporting person to receive one share of Oncology Institute’s common stock upon settlement, according to the grant’s terms described in the insider transaction footnote.
Was the TOI director’s July 27, 2026 RSU grant a market purchase or a compensation award?
The transaction is coded as a grant or award acquisition, not a market purchase. The RSUs were awarded at a reported price of $0.0000 per share, reflecting a stock-based compensation grant rather than an open-market buy.